Goldfinch Bio inks $100m Series B

Cambridge, Massachusetts-based Goldfinch Bio, a clinical stage biotechnology company focused on treating kidney diseases, has raised $100 million in Series B financing.

Cambridge, Massachusetts-based Goldfinch Bio, a clinical stage biotechnology company focused on treating kidney diseases, has raised $100 million in Series B financing. Eventide Asset Management led the round with participation from other investors that included Wellington Management Company, Ally Bridge Group, BlackRock, Casdin Capital LLC and Irving Investors.

Source: Press Release